Reader-Supported · Editorially Reviewed
Evidence Watch · Peer-reviewed oral-semaglutide trial

15.1% Average Loss With Oral Semaglutide at 68 Weeks

OASIS 1 evaluated an oral semaglutide regimen escalated to 50 mg daily in adults without type 2 diabetes. The 68-week trial reported average weight loss under defined eligibility and lifestyle-intervention conditions. The studied 50 mg dose should not be treated as the same as the currently listed U.S. 25 mg oral maintenance dose.

Last reviewed September 2026
1 study cited
The LancetPhase 3, multicenter, double-blind, randomized, placebo-controlled superiority trial68 weeks
The study result

At week 68, estimated mean body-weight change was −15.1% with oral semaglutide 50 mg and −2.4% with placebo.

At least 5% weight loss occurred in 85% of semaglutide participants and 26% of placebo participants. Gastrointestinal adverse events occurred in 80% and 46%, respectively, and were mostly mild to moderate. The study used a 50 mg daily regimen; it did not compare the currently listed U.S. 25 mg oral maintenance dose.

Compare programs

Turn the study result into a better program comparison

If this oral-semaglutide result prompts you to explore GLP-1 care, compare the practical details the study cannot answer: available medication forms, clinician access, product status, public price terms, follow-up, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.

01
WellMedr logo
WellMedr

From $49 – $129/mo · Editorial score 4.7/5

Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.

Semaglutide at WellMedr
02
Strut Health logo
Strut Health

From $149 – $399/mo · Editorial score 4.6/5

Semaglutide at Strut Health
03
Trimi logo
Trimi

From $99 – $125/mo · Editorial score 4.8/5

Tirzepatide at Trimi
04
Telos Rx logo
Telos Rx

From $49 – $399/mo · Editorial score 3.9/5

Tirzepatide at Telos Rx
05
HealthRx logo
HealthRx

From $99 – $209/mo · Editorial score 4.1/5

Semaglutide at HealthRx
06
Cielo Health logo
Cielo Health

From $115 – $299/mo · Editorial score 4.4/5

Tirzepatide at Cielo Health

We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology

Study details

Population
667 adults without type 2 diabetes who had obesity, or overweight plus a weight-related complication
Follow-up
68 weeks
Treatment comparison
Oral semaglutide escalated to 50 mg once daily compared with matching placebo, with lifestyle intervention
Study design
Phase 3, multicenter, double-blind, randomized, placebo-controlled superiority trial
Care and plan considerations

A study result is not a personal treatment plan

This was a study of a 50 mg daily oral regimen, not a provider comparison and not a finding that any online program offers that studied dose. Current labeled products, available tablet strengths, prescription suitability, insurance terms, and dose progression should be reviewed with a licensed clinician and current prescribing information.

Compare semaglutide and tirzepatide programs

What this result does not show

  • The trial lasted 68 weeks and does not establish durability of weight change or safety after treatment discontinuation.
  • Adults with type 2 diabetes were excluded, so the findings do not directly apply to that population.
  • The trial compared the 50 mg regimen with placebo rather than another active obesity treatment or the currently listed U.S. 25 mg oral maintenance dose.
  • The sample size and follow-up were not designed to reliably characterize rare or longer-latency harms.
  • The study was funded by Novo Nordisk; the peer-reviewed paper and disclosure materials are linked at the end of this article.
Not sure which provider fits you? Take the 30-second quiz
Answer 4 quick questions to get a personalized provider match
Continue reading

Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.

All study updates
Study & references

Primary peer-reviewed source

Knop et al., Lancet 2023 · OASIS 1

Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.

Read the study at The Lancet